LLY · ELI LILLY & Co · Webcasts, Transcripts & Audio
$1,282.59
+9.13 (+0.72%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$1.20T
Shares
941.36M
Volume · Oct 26
2.1M
Avg daily vol (3M)
2.49M
ELI LILLY & Co Webcasts
Earnings calls, investor updates, investor days and conferences for ELI LILLY & Co (LLY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
ELI LILLY & Co (LLY) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
ELI LILLY & Co (LLY) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
ELI LILLY & Co (LLY) Q2 2026 Earnings Call Transcript
Confident tone
Foundeo (orforglipron) Oral GLP-1 Launch and Expansion
International Ex-U.S. Launch Execution and Reimbursement
Pipeline Advancement and R&D Investment
Revenue
$22.97B
▲ 47.7% YoY Diluted EPS
$7.94
▲ 26.2% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
ELI LILLY & Co (LLY) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Investor Update
Investor event
2026-06-06
ELI LILLY & Co (LLY) June 6, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
ELI LILLY & Co (LLY) Q1 2026 Earnings Call Transcript
Confident tone
Foundayo (orforglipron) oral GLP-1 launch
Pipeline advancement and Phase III programs
Zepbound and Mounjaro growth
Revenue
$19.80B
▲ 55.5% YoY Diluted EPS
$8.26
▲ 169.9% YoY Gross margin
81.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-04
ELI LILLY & Co (LLY) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline and R&D
Incretin franchise (Mounjaro/Zepbound)
Direct-to-patient / self-pay platform
Revenue
$19.29B*
▲ 42.5% YoY Gross margin
82.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
ELI LILLY & Co (LLY) Q3 2025 Earnings Call Transcript
Confident tone
Pipeline and Regulatory Approvals
International Growth and Launches
Revenue and Earnings Growth
Revenue
$17.60B
▲ 53.9% YoY Diluted EPS
$6.21
▲ 480.4% YoY Gross margin
82.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
ELI LILLY & Co (LLY) Q2 2025 Earnings Call Transcript
Confident tone
Orforglipron obesity pipeline
Incretin franchise performance (Mounjaro/Zepbound)
LillyDirect direct-to-consumer channel
Revenue
$15.56B
▲ 37.6% YoY Diluted EPS
$6.29
▲ 91.8% YoY Gross margin
84.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
ELI LILLY & Co (LLY) Q1 2025 Earnings Call Transcript
Confident tone
Orforglipron Oral GLP-1 Pipeline
Revenue Growth and Key Products
Zepbound Access and Reimbursement
Revenue
$12.73B
▲ 45.2% YoY Diluted EPS
$3.06
▲ 23.4% YoY Gross margin
82.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-14
ELI LILLY & Co (LLY) Q4 2024 Earnings Call Transcript
Confident tone
Pipeline and R&D Milestones
Regulatory Approvals and New Launches
Mounjaro and Zepbound (Incretin) Momentum
Revenue
$13.53B*
▲ 44.7% YoY Gross margin
82.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
ELI LILLY & Co (LLY) Q3 2024 Earnings Call Transcript
Confident tone
Incretin franchise (Mounjaro/Zepbound) supply and access
Revenue and financial performance
Pipeline progress and approvals
Revenue
$11.44B
▲ 20.4% YoY Diluted EPS
$1.07
Gross margin
81.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
ELI LILLY & Co (LLY) Q2 2024 Earnings Call Transcript
Confident tone
Mounjaro and Zepbound supply expansion
Tirzepatide label expansion (OSA, HFpEF)
Obesity pipeline breadth
Revenue
$11.30B
▲ 36% YoY Diluted EPS
$3.28
▲ 68.2% YoY Gross margin
80.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
ELI LILLY & Co (LLY) Q1 2024 Earnings Call Transcript
Confident tone
Tirzepatide / Mounjaro / Zepbound growth
Manufacturing capacity expansion
NASH / liver disease opportunity
Revenue
$8.77B
▲ 26% YoY Diluted EPS
$2.48
▲ 66.4% YoY Gross margin
80.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-06
ELI LILLY & Co (LLY) Q4 2023 Earnings Call Transcript
Confident tone
Diabetes & Obesity Portfolio (Incretins)
Pipeline Progress & Clinical Trials
Manufacturing Capacity & Supply Constraints
Revenue
$9.35B*
▲ 28.1% YoY Gross margin
80.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
ELI LILLY & Co (LLY) Q3 2023 Earnings Call Transcript
Revenue
$9.50B
▲ 36.8% YoY Diluted EPS
$-0.06
▼ 103.7% YoY Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
ELI LILLY & Co (LLY) Q2 2023 Earnings Call Transcript
Revenue
$8.31B
▲ 28.1% YoY Diluted EPS
$1.95
▲ 85.7% YoY Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
ELI LILLY & Co (LLY) Q1 2023 Earnings Call Transcript
Revenue
$6.96B
▼ 10.9% YoY Diluted EPS
$1.49
▼ 29% YoY Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-02
ELI LILLY & Co (LLY) Q4 2022 Earnings Call Transcript
Revenue
$7.30B*
▼ 8.7% YoY Gross margin
78.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-12-13
ELI LILLY & Co (LLY) Q3 2022 Earnings Call Transcript
Revenue
$6.94B
▲ 2.5% YoY Diluted EPS
$1.61
▲ 32% YoY Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
ELI LILLY & Co (LLY) Q2 2022 Earnings Call Transcript
Revenue
$6.49B
▼ 3.7% YoY Diluted EPS
$1.05
▼ 31.4% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-14
ELI LILLY & Co (LLY) Q1 2022 Earnings Call Transcript
Revenue
$7.81B
▲ 14.8% YoY Diluted EPS
$2.10
▲ 40.9% YoY Gross margin
73.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
ELI LILLY & Co (LLY) Q4 2021 Earnings Call Transcript
Revenue
$8.00B*
▲ 7.5% YoY Gross margin
74.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-26
ELI LILLY & Co (LLY) Q3 2021 Earnings Call Transcript
Revenue
$6.77B
▲ 18% YoY Diluted EPS
$1.22
▼ 8.3% YoY Gross margin
78.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
ELI LILLY & Co (LLY) Q2 2021 Earnings Call Transcript
Revenue
$6.74B
▲ 22.6% YoY Diluted EPS
$1.53
▼ 1.3% YoY Gross margin
71.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-27
ELI LILLY & Co (LLY) Q1 2021 Earnings Call Transcript
Revenue
$6.81B
▲ 16.1% YoY Diluted EPS
$1.49
▼ 6.9% YoY Gross margin
72.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-29
ELI LILLY & Co (LLY) Q4 2020 Earnings Call Transcript
Revenue
$7.44B*
▲ 21.7% YoY Gross margin
76.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
ELI LILLY & Co (LLY) Q3 2020 Earnings Call Transcript
Revenue
$5.74B
▲ 4.8% YoY Diluted EPS
$1.33
▼ 2.9% YoY Gross margin
76.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
ELI LILLY & Co (LLY) Q2 2020 Earnings Call Transcript
Revenue
$5.50B
▼ 2.4% YoY Diluted EPS
$1.55
▲ 7.6% YoY Gross margin
77.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-23
ELI LILLY & Co (LLY) Q1 2020 Earnings Call Transcript
Revenue
$5.86B
▲ 15.1% YoY Diluted EPS
$1.60
▼ 62.9% YoY Gross margin
79.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
ELI LILLY & Co (LLY) Q4 2019 Earnings Call
Revenue
$6.11B
▲ 8.5% YoY Diluted EPS
$1.64
▲ 49.1% YoY Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 webcasts
Key facts
CIK
59478
CUSIP
532457108
13F (30d)
1562 filings
1527 filers
Visit website
Investor relations